Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Biosimilar Trastuzumab-anns for All Approved Herceptin Indications

Jun 14, 2019, 10:12 AM
URL:
On June 13, 2019, Amgen and Allergan plc announced the U.S. Food and Drug Administration (FDA) has approved Kanjinti (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Read corporate press release.

Posted 6/14/2019

Leave a comment